MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level
Authors:
- Yael HaringYHYael Haring
- Noa GoldschmidtNGNoa Goldschmidt
- Shaimaa TahaSTShaimaa Taha
- Galia StemerGSGalia Stemer
- Kalman FilanovskyKFKalman Filanovsky
- Ilana HellmanIHIlana Hellman
- Doaa OkashaDODoaa Okasha
- Baher KrayemBKBaher Krayem
- Itai LeviILItai Levi
- Hanna RosenbaumHRHanna Rosenbaum
- Maya Koren-MichowitzMKMaya Koren-Michowitz
- Shai YagnaSYShai Yagna
Open Access
- 9 September 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5865
Abstract
Quality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb–QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent). The anemia subgroups were: none/normal (Hb ≥ 12.5 g/dL), mild (10 ≤ Hb < 12.5), moderate (9 ≤ Hb < 10), severe (8 ≤ Hb < 9), or very severe (Hb < 8). LR-MDS patients (n = 127) and inpatient controls (n = 141) participated. The anemic patients had a poor QoL and the MDS patients had a lower QoL with a lower Hb. The controls had no QoL difference among the various anemia subgroups. In addition, the MDS QoL sharply decreased with an Hb of < 9. The MDS patients showed a wide QoL variability, i.e., different QoL scores in the same Hb subgroup, suggesting that other factors affect QoL (e.g., age and comorbidities). After 1 year (n = 61), the QoL was still poor for most MDS patients (including 27 patients with an increased Hb). In summary: (1) a poor QoL in MDS-anemia is non-linear, suggesting other influencing factors on QoL. (2) The sharp QoL drop with Hb < 9 g/dL challenges the transfusion Hb threshold. (3) The QoL in anemic MDS patients might differ from that in non-MDS patients. (4) Raising Hb, while recommended, does not guarantee an improved QoL.Keywords
This publication has 46 references indexed in Scilit:
- Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryBritish Journal of Haematology, 2015
- Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of lifeBlood, 2014
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based surveyLeukemia Research, 2008
- Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndromeLeukemia Research, 2005
- The F unctional A ssessment of C hronic I llness T herapy (FACIT) Measurement System: properties, applications, and interpretationHealth and Quality of Life Outcomes, 2003
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- EuroQol: the current state of playHealth Policy, 1996